Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of the uptake transporters organic anion transporter 1 and/or 3 (OAT1, OAT3) may increase the plasma concentration of edaravone sulfate, the active metabolite of edaravone, which is a substrate for these transporters. However, data from in vivo studies are lacking.

MANAGEMENT: Caution is advised if edaravone is used concomitantly with OAT1 and/or OAT3 inhibitors. Dosage adjustments as well as clinical monitoring of edaravone therapy should be considered whenever an OAT1 and/or OAT3 substrate is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.

Consumer information for this interaction is not currently available.

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.